key: cord-1017842-z3msyl45
authors: Kilpeläinen, Athina; Jimenez-Moyano, Esther; Blanch-Lombarte, Oscar; Ouchi, Dan; Peña, Ruth; Quirant-Sanchez, Bibiana; Chamorro, Anna; Blanco, Ignacio; Martínez-Caceres, Eva; Paredes, Roger; Mateu, Lourdes; Carrillo, Jorge; Blanco, Julià; Brander, Christian; Massanella, Marta; Clotet, Bonaventura; Prado, Julia G.
title: Highly functional Cellular Immunity in SARS-CoV-2 Non-Seroconvertors is associated with immune protection
date: 2021-05-04
journal: bioRxiv
DOI: 10.1101/2021.05.04.438781
sha: a9c161a0b78cbc092cc1500448371639d5b6338f
doc_id: 1017842
cord_uid: z3msyl45

The role of T cells in the control of SARS-CoV-2 infection has been underestimated in favor of neutralizing antibodies. However, cellular immunity is essential for long-term viral control and protection from disease severity. To understand T-cell immunity in the absence of antibody generation we focused on a group of SARS-CoV-2 Non-Seroconvertors (NSC) recovered from infection. We performed an immune comparative analysis of SARS-CoV-2 infected individuals stratified by the absence or presence of seroconversion and disease severity. We report high levels of total naïve and low effector CD8+ T cells in NSC. Moreover, polyfunctional Nucleocapsid (NP)-specific CD8+ T-cell responses, as well as reduced levels of T-cell activation monitored by PD-1 and activation-induced markers, were distinctive immunological traits in NSC. Longitudinal data support the stability of the NSC phenotype over three months. Our results implicate highly functional SARS-CoV-2 Spike and NP T-cell responses with low immune activation in protection from disease severity in the absence of seroconversion. SUMMARY To understand SARS-CoV-2 specific T-cell immunity in the absence of seroconversion, we characterized immunological features of Non-Seroconvertors recovered from infection. Highly functional specific T-cell responses and low immune activation were determinants of immune protection from severe disease.

The COVID-19 pandemic is caused by SARS-CoV-2, the newest coronavirus crossing into the 62 human population. The pandemic accounts for millions of infected people and more than 2 million 63 deaths worldwide. Despite the scientific success in rapidly generating SARS-CoV-2 vaccines, the 

The KING extension cohort is composed of 336 SARS-CoV-2 infected individuals, including 120 128 individuals who required hospitalization, 22% of whom with severe or critical SARS-CoV-2 129 infection (Fig 1A) . For the present study we identified participants (N=52) (median age 47 years, 130 62% female, 38% male) across Non-Seroconvertors (NSC, n=16), Low-neutralizers (LN, N=16) 131 and Convalescent (Conv, N=15) (Fig 1A) . Also, we obtained samples from healthy donors from 

The presence of anti-SARS-CoV-2 antibodies in serum or plasma samples was evaluated using 148 two independent Enzyme-linked Immunosorbent Assays (ELISA). The first was an in-house 149 developed sandwich-ELISA. Briefly, Nunc MaxiSorp ELISA plates were coated overnight at 4ºC 150 with 50 ml of capture antibody (anti-6xHis antibody, clone HIS.H8; ThermoFisher Scientific) at 151 2 mg/mL in PBS. After washing, plates were blocked for two hours at room temperature using 152 PBS containing 1% of bovine serum albumin (BSA, Miltenyi biotech). 50 ml (1mg/mL in 153 blocking buffer) of the following SARS-CoV-2 derived antigens: S1+S2 subunits of the Spike 154 (S) protein and receptor-binding domain (RBD, Sino Biological) were subsequently added and 155 incubated overnight at 4ºC. Each plasma sample was evaluated in duplicates at a 1/100 dilution 156 in blocking buffer for each antigen. Antigen free wells were also assessed in parallel for each 8 Pseudovirus neutralization assay.

HIV reporter pseudoviruses expressing SARS-CoV-2 S protein and Luciferase were generated. 183 pNL4-3.Luc.R-.E-was obtained from the NIH AIDS repository (Connor RI, Chen BK, 195) . 

To measure SARS-CoV-2 specific T-cell responses, cryopreserved PBMCs were stimulated with rank correlation coefficient test was used for correlation analysis. Non-parametric ANOVA was 238 used to compare differences in age between study groups and was adjusted for multiple 239 comparisons (Dunn's test). In the analysis of T-cell subsets, median values within phenotypes 240 were normalized to 100%. Single-cell analysis were performed using the statistical package R 241 (v3.6.3). Cells were compensated and selected based on its antigen expression (TNF, IL-2 and 242 IFN-γ intensity) and normalized before performing UMAP dimensionality reduction. We used 243 FlowJo 10.0.7 for the graphical representation of the single-cell analysis. 

and compared between study groups (Fig 1A, S1A-B) . No alterations in total frequencies of CD3+ 255 T cells or CD4+/CD8+ ratios were found between SARS-CoV-2 study groups nor when compared 256 with healthy donors (data not shown). By contrast, analysis of CD4+ T-cell subsets revealed 257 higher levels of CD4+ T naïve cells in NSC compared to LN and (p=0.0084, Fig 1B) Fig 1B) . No significant differences were observed regarding the 260 distribution of the other CD4+ T-cell subsets (Fig 1B) . Interestingly, we observed marked 261 differences in CD8+ T-cell subsets, when comparing NSC and Conv groups (Fig 1C) .

Specifically, NSC had significantly higher frequencies of CD8+ T naïve (TN, median 44.6% vs 263 14.3%; p=0.0004) and significantly lower frequencies of CD8+ T effector cells (TEF) (median 264 5.6% vs 35.8%; p=0.0007, Kruskal-Wallis). In NSC, the observed T-cell subset distribution was 265 stable up to a median of 92.5 days of follow-up after infection (Fig S1C-D) . To assess whether 266 the difference in CD8+ TN and TEF distribution in NSC was related to the individuals' age or to 267 days from symptom onset (DfSO), we performed correlation analyses. We did not find a By contrast, there was a significant negative correlation between frequency of CD8+ TN and age 270 (Spearman r -0.5596, p=0.0257 and r-0.6553, p=0.0091) and a significant positive correlation 271 between frequency of CD8+ TEF and age (r= 0.5420, p= 0.0321 and r=0.6732, p= 0.0073) in the 272 LN and Conv groups, respectively (Fig 1D-E) . Similarly, while we did not find a significant 273 correlation between DfSO and CD8+ TN or TEF in NSC, a negative correlation between CD8+ 274 TEF % and DfSO in Conv (r= -0.5429, P=0.0391) was observed (Fig 1F-G) . Taken together, staining for IFN-γ, IL-2 and TNF production (Fig 2) . Visualization of cytokine profiles in antigen 286 specific T cells as performed by UMAP analysis is represented in Fig S2. Analysis of S and NP-287 specific CD4+ T-cell responses revealed antigen-specific cytokine production in all study groups 288 (Fig 2A) and no significant differences in the frequency of S and NP-specific CD4+ T cells 289 between NSC and the other SARS-CoV-2 groups for any of the cytokines studied. However, LN 290 displayed significantly lower NP-specific IFN-γ production than Conv (p=0.0402). Lack of 291 statistically significant differences between NSC and Conv might be associated with the high 12 interindividual variability, despite the lower median frequency of NP-specific CD4+ T cell 293 responses in NSC vs. Conv individuals. The difference in median frequency was particularly 294 marked for the proinflammatory cytokine TNF in NSC compared to Conv (0.07% vs 1% in TNF, 295 0.01% vs 0.3% in IFN-γ and 0% vs 0.26% in IL-2, respectively; Fig 2A) . Similarly to SARS-

CoV-2-specific CD4+ T cells, S and NP-specific CD8+ T-cell responses were present in all study 297 groups. No statistically significant differences were found between them and marked 298 interindividual variability was observed (Fig 2B) . Also, median frequencies of IFN-γ or TNF 299 producing NP-specific CD8+ T cells were lower in NSC vs Conv (0.06% vs 0.23% in TNF and 300 0.05% vs 0.24% for IFN-γ, respectively; Fig 2B) . Next, we determined the frequency of T-cell 301 cytokine responders across study groups defined by the presence of either S or NP CD4+ or CD8+

T cells producing at least one cytokine and using a threshold of 0.2% cut-off for a positive 303 response after background subtraction. Overall, the frequency of SARS-CoV-2 responders were 304 81% in NSCs, 75% in LN, 80% in Conv, and 20% of healthy donors. Distributed by SARS-CoV-305 2 proteins, we observed a frequency of S responders in 56% of NSCs, 50% of LN, 53% of Conv, were observed in all groups (Fig 2C) . In response to NP proteins, CD4+ T cells of NSCs displayed 328 similar characteristics as did Conv (with 2.4% vs 4.9% trifunctional cells, and 26.1% vs 31.1% 329 bifunctional cells respectively) (Fig 2D) . Interestingly, NSC had the highest frequencies of 330 trifunctional NP-specific CD8+ T cells, accounting for 16% of their NP-specific CD8+ T cells, 331 compared with LN and Conv (5.2% and 1.2%, respectively, Fig 2D) . By contrast, no major 332 differences in mono and bifunctional CD8+ T cells between groups were observed (Fig 2D) .

These results demonstrate a particularly elevated frequency of highly functional SARS-CoV2- and AIMs using antibodies directed against CD25, OX40 and CD137 and PD-1 in unstimulated 343 and S-and NP-antigen stimulated conditions (Fig 3A-C) . As observed for SARS-CoV-2-specific 344 T-cell cytokine production, a high level of interindividual variability was observed within groups 345 for AIMs. Still, we found statistically significantly lower expression of CD25 + OX40 + CD4 + T 346 cells in response to S in NSC compared to Conv (median 0.13% vs 0.59%, respectively, p=0.0216, Fig 3B) . The same was observed for S-specific CD4+ CD137 + OX40 + T cells (p=0.0117, data not shown). In addition, CD25 + OX40 + CD4+ T cells in response to NP were not significantly different 349 between NSC and the rest of the groups, although lower median frequencies were observed 350 (0.005% NSC vs 0.84% Conv, Fig 3B) . The analysis of AIM on CD8+ T cells did not reveal 351 significant differences in CD137 + CD8 + T-cell frequencies between study groups (Fig 3B) .

However, the median frequency of CD137 + CD8 + T cells was lower in NSC, particularly in 353 response to NP (0% NSC vs 0.77% Conv, Fig 3B) . Also, we performed longitudinal follow-up 

The low levels of CD8+ TEF observed in NSC could partially be explained by highly functional 423 CD8+ T cells, overcoming the need for a large proportion of effector cells.

and CD8+ T-cell responses by cytokine production and AIMs in response to S and NP proteins.

Overall, we did not observe differences in cytokine production in CD4+ and CD8+ T cells in 427 response to S and NP proteins in NSC and the rest of the groups, which may have been due to the 428 marked interindividual variability in these parameters. This is in partial agreement with data 

Our study has some limitations. First, we found a bias in epidemiological characteristics in NSC 492 toward a high frequency of females and median lower age. Second, we used S and NP 493 recombinant proteins as opposed to optimal peptides for the study of antigen-specific T cells, 

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous 623 prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 624 trial in Russia

639 Longitudinal analyses reveal immunological misfiring in severe COVID-19

Covid-19: Moderna applies for US and EU approval as vaccine trial reports 642 94.1% efficacy

The lasting misery of coronavirus long-haulers

678 and K. Kedzierska. 2021. CD8+ T cells specific for an immunodominant SARS-CoV-2 679 nucleocapsid epitope display high naïve precursor frequency and T cell receptor 680 promiscuity

Is Related to Low Frequency of Infected Cells and Inefficient Viral Reactivation

The Advisory Committee on Immunization 689

Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine -690

United States

Characterization of spike 694 glycoprotein of SARS-CoV-2 on virus entry and its immune

The major genetic determinants of HIV-1 control affect HLA class I 723 peptide presentation. Science (80-. )

Stable neutralizing 728 antibody levels 6 months after mild and severe COVID-19 episodes

Comparative analysis of activation induced marker (AIM) assays for sensitive 735 identification of antigen-specific CD4 T cells

PD-1-Expressing SARS-CoV-2-Specific CD8+ T Cells Are Not Exhausted, but 741 Functional in Patients with COVID-19

Evolution of the Inflammatory Response in Vertebrates: Fish TNF-α Is a 745

Powerful Activator of Endothelial Cells but Hardly Activates Phagocytes

Alternative 750 effector-function profiling identifies broad HIV-specific T-cell responses in highly HIV-751 exposed individuals who remain uninfected

Antigen-Specific Adaptive Immunity

CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity

Characterization of pre-existing and induced SARS-CoV-2-specific CD8+ T cells

Cellular Immunity in COVID-19 Convalescents with

Infection but with Undetectable SARS-CoV-2-Specific IgG

T-cell quality in memory and protection: 772 Implications for vaccine design

Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild Patil, and V. Patel. 2020. Delineation of Homeostatic Immune Signatures Defining 789

Viremic Non-progression in HIV-1 Infection

Igg seroconversion and pathophysiology in severe acute respiratory 798 syndrome coronavirus 2 infection

Sex differences in immune responses that 814 underlie COVID-19 disease outcomes